Novartis released updated data for its MS candidate siponimod (aka BAF312) over the weekend which showed it can cut the risk of patients’ disability…

Days after Eli Lilly announced that Richard Gaynor, its SVP of clinical development for its oncology biz, would be retiring, the Big Pharma has announced a…

Novo Nordisk has shown that its once-weekly experimental injectable diabetes med semaglutide can cut a number of cardiovascular events by 26% in Type 2…

Novavax saw its shares plummet afterhours yesterday when it announced a late-stage test of its infectious respiratory disease vaccine missed all of its marks…

Roche’s new multiple sclerosis drug has beaten out the aging MS treatment Rebif (interferon beta-1a) in a head-to-head late-stage test as it looks to a…

GlaxoSmithKline and partner Johnson & Johnson have submitted their next-gen IL-6 arthritis med sirukumab to the EMA a month before rivals Regeneron and…

Shares in Clovis Oncology jumped yesterday on the news that the FDA will forgo its usual external panel review for its PARP drug rucaparib in what some…

Japan has warned the United Kingdom that its drugmakers may refocus their R&D activities on mainland Europe following Brexit.

Moderna is edging toward a total $2 billion in funding after just 5 years of life after announcing a major new funding round--which coincides with a potential…